Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytoprotective agents for anthracyclines

R T Dorr1

  • 1Department of Pharmacology/Toxicology, Arizona Cancer Center, College of Medicine, University of Arizona, Tucson 58724, USA.

Seminars in Oncology
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemistry and pharmacology of imexon and related cyanoaziridines.

Current medicinal chemistry·2012
Same author

Adult rat myocardial slices: A tool for studies of comparative cardiotoxicity.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.

Bone marrow transplantation·2003
Same author

Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.

Journal of medicinal chemistry·2001
Same author

Drug interactions with the taxanes: clinical implications.

Cancer treatment reviews·2001
Same author

Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.

Anti-cancer drugs·2001
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Amifostine (WR-2721) shows potential in protecting the heart from doxorubicin-induced damage by scavenging reactive oxygen species. Preclinical studies suggest it may reduce cardiotoxicity without compromising antitumor effects, warranting further investigation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Oncology

Background:

  • Anthracycline chemotherapy, like doxorubicin, can cause cardiotoxicity due to reactive oxygen species generation.
  • Existing antioxidants have failed to prevent doxorubicin-induced heart damage in patients.
  • Dexrazoxane (ICRF-187) is a known cardioprotective agent against doxorubicin but has limitations.

Purpose of the Study:

  • To evaluate the cardioprotective potential of amifostine (WR-2721) against anthracycline-induced cardiotoxicity.
  • To investigate the mechanisms of amifostine's cytoprotective effects in cardiac cells.
  • To assess amifostine's impact on doxorubicin's efficacy and toxicity in preclinical models.

Main Methods:

  • In vitro studies using neonatal rat heart cells exposed to doxorubicin.

Related Experiment Videos

  • Evaluation of amifostine and its active metabolite WR-1065 for reactive oxygen species scavenging.
  • In vivo studies in tumor-bearing mice treated with doxorubicin and amifostine.
  • Assessment of myocyte adenosine triphosphate levels after sulfhydryl pretreatment.

    • Main Results:

    • Amifostine and WR-1065 demonstrated in vitro cardioprotection against doxorubicin.
    • Amifostine reduced doxorubicin lethality in mice without affecting antitumor activity.
    • Pretreatment with amifostine prevented doxorubicin-induced decreases in myocyte ATP levels.
    • Cytoprotective drug levels of amifostine were achieved in vitro.

    Conclusions:

    • Amifostine exhibits promising cytoprotective activity against doxorubicin-induced cardiac damage.
    • Further animal studies in chronic doxorubicin models are indicated.
    • Positive results may lead to clinical trials to test amifostine's cardioprotective efficacy in patients.